Literature DB >> 10492284

Vascular endothelial growth factor in pleural fluid.

D Cheng1, R M Rodriguez, E A Perkett, J Rogers, G Bienvenu, U Lappalainen, R W Light.   

Abstract

STUDY
OBJECTIVES: The purpose of this study was to analyze the relationship of the pleural fluid vascular endothelial growth factor (VEGF) level with the diagnostic category and with the pleural fluid characteristics in a group of 70 patients.
DESIGN: The VEGF levels of consecutive patients undergoing therapeutic thoracentesis were determined with an enzyme-linked immunosorbent assay.
SETTING: University-affiliated tertiary care center.
RESULTS: The median level of pleural fluid VEGF in the patients with congestive heart failure (150 pg/mL) was significantly (p < 0.05) lower than the median level in the patients with coronary artery bypass grafting (357 pg/mL), which in turn was significantly lower (p < 0.05) than the median levels in the patients with malignancy (1,097 pg/mL). The overlap between groups, however, limits the diagnostic usefulness of pleural fluid VEGF levels. The VEGF level was most closely correlated with the lactate dehydrogenase level (r = 0.42, p < 0.001) and was also significantly correlated with the total pleural fluid protein level. The median VEGF levels in the pleural fluid of patients with breast cancer were significantly lower (p = 0.017) than in those with lung cancer. The VEGF level was very high (3,294 pg/mL) in the one patient with pulmonary embolism.
CONCLUSIONS: We conclude that the VEGF levels in pleural fluid differ significantly from one diagnostic category to another with the highest median levels occurring in patients with malignant pleural effusions. We speculate that VEGF may be responsible for the pleural fluid accumulation in at least some situations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492284     DOI: 10.1378/chest.116.3.760

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

1.  Potential role of AQP1 and VEGF in the development of malignant pleural effusion in mice.

Authors:  Jing Xuan Zhang; C M Xie; Z W Zhu; H Y Huang; Z L Zeng
Journal:  Med Oncol       Date:  2011-04-26       Impact factor: 3.064

2.  Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure.

Authors:  H Arakawa; U Ikeda; Y Hojo; S Ueno; M Nonaka-Sarukawa; K Yamamoto; K Shimada
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

Review 3.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

4.  Pleural effusions as a predictive parameter for poor prognosis for patients with acute pulmonary thromboembolism.

Authors:  Xia Zhou; Zhu Zhang; Zhenguo Zhai; Yunxia Zhang; Ran Miao; Yuanhua Yang; Wanmu Xie; Jun Wan; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

5.  A potential role for VEGF in the diagnostic approach of pleural effusions.

Authors:  Aggeliki Psatha; Demosthenes Makris; Theodora Kerenidi; Zoe Daniil; Theodoros Kiropoulos; Konstantinos Gourgoulianis
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

6.  Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysis.

Authors:  Yong-Chun Shen; Meng-Qi Liu; Chun Wan; Lei Chen; Tao Wang; Fu-Qiang Wen
Journal:  Exp Ther Med       Date:  2012-03-14       Impact factor: 2.447

7.  Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.

Authors:  Motohiro Tamiya; Akihiro Tamiya; Tadahiro Yamadori; Keiko Nakao; Kazuhiro Asami; Tomomi Yasue; Tomoyuki Otsuka; Takayuki Shiroyama; Naoko Morishita; Hidekazu Suzuki; Norio Okamoto; Kyoichi Okishio; Tomoya Kawaguchi; Shinji Atagi; Ichiro Kawase; Tomonori Hirashima
Journal:  Med Oncol       Date:  2013-08-08       Impact factor: 3.064

8.  Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.

Authors:  Katsuhiro Masago; Daichi Fujimoto; Shiro Fujita; Akito Hata; Reiko Kaji; Kyoko Ohtsuka; Chiyuki Okuda; Jumpei Takeshita; Nobuyuki Katakami
Journal:  Mol Clin Oncol       Date:  2014-11-19

9.  Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions.

Authors:  Eva Ruiz; Carmen Alemán; José Alegre; Jasone Monasterio; Rosa Ma Segura; Lluis Armadans; Ana Vázquez; Teresa Soriano; Tomás Fernández de Sevilla
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

10.  Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion.

Authors:  Seong Hwan Choi; Eun Young Park; Hye Lim Jung; Jae Won Shim; Deok Soo Kim; Moon Soo Park; Jung Yeon Shim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.